Shimizu, K., Sunagawa, Y., Funamoto, M., Honda, H., Katanasaka, Y., Murai, N., . . . Morimoto, T. (2021). The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway. MDPI AG.
Chicago Style (17th ed.) CitationShimizu, Kana, et al. The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway. MDPI AG, 2021.
MLA (9th ed.) CitationShimizu, Kana, et al. The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2–GATA4 Signaling Pathway. MDPI AG, 2021.
Warning: These citations may not always be 100% accurate.